Besides, studies have clarified that ROCK inhibitors showed a promising outlook on K-Ras–induced glioma, lung cancers and hematological malignancies (Nakabayashi and Shimizu, 2011; Rath and Olson, 2012). This evidence concerns the gene KRAS and lung carcinoma.